Individualizing chemotherapy for non-small cell lung cancer (NSCLC) in the adjuvant and advanced setting: current status and future directions.
Treatments based on molecular determinants are likely to be increasingly explored in the future. Future challenges will include ensuring that molecular determinants are identified as novel chemotherapeutic agents are being developed, enabling rationale therapeutics. Clinical trials will then enrich patients with the molecular determinants, potentially increasing response rates and survival in a specific group of patients who express this molecular determinant. It is hoped that this patient-specific 'individualized cocktails' will substantially improve response rates and survival.
Simon
George R
GR
Thoracic Oncology Program for Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA. george.simon@fccc.edu
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D005544:Forecasting; D015870:Gene Expression; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D008957:Models, Genetic; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D013997:Time Factors
D000970:Antineoplastic Agents